Company intelligence / Profile preview
BridGene Biosciences
San Jose, California, United Statesbridgenebio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
BridGene has advanced its lead program BGC‑515 targeting TEAD into Phase I clinical trials for solid tumors. Other pipeline assets are in preclinical development. The company’s IMTAC™ platform enables the identification of small molecules against previously undruggable targets. Multiple high-value partnerships have been established with major pharma companies such as Takeda and Galapagos to discover novel therapeutics in oncology, immunology, and neurology. No published late-stage clinical results as of May 2025.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesPROTACs (Proteolysis Targeting Chimeras)
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceutical Co.: Multi-program collaboration using IMTAC™ platform for immunology & neurology ($816M+ deal value including milestones/upfronts)Galapagos NV.: Collaboration on selective oral SMARCA2 PROTAC development in precision oncology; Galapagos holds exclusive rights to further develop/commercialize resulting candidates.
Beyond the preview
Go deeper on BridGene Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BridGene Biosciences.